Virtuix Holdings Inc. (NASDAQ: VTIX) announced that Rutgers University has deployed the company's Omni One omni-directional treadmill platform at WINLAB for research focused on AI-assisted neurodivergent therapy and behavioral analytics applications, including autism therapy for children.

The collaboration will explore how immersive virtual environments combined with full-body movement and adaptive AI interaction may enhance engagement and learning outcomes in therapeutic settings. Researchers plan to evaluate patients' attention, movement patterns, response timing, engagement consistency, and spatial interaction over time.

"We believe movement-centered, AI-enabled virtual reality represents a significant emerging opportunity across therapy, rehabilitation, and other healthcare applications," said Jan Goetgeluk, Chief Executive Officer of Virtuix. "By introducing full-body movement and AI interaction through Omni One, we are enabling entirely new categories of user engagement beyond traditional VR experiences."

Dr. Yingying Chen, Department Chair and Distinguished Professor of Electrical and Computer Engineering at Rutgers University, stated that the collaboration allows exploration of how VR immersion combined with full-body locomotion and AI may create new approaches for neurodevelopmental therapy.

The initiative follows a recent Omni One deployment to Florida Gulf Coast University for evaluation in rehabilitation and clinical simulation applications. While Virtuix's primary focus remains on consumer entertainment and defense applications, the company indicated that full-body movement within AI-enabled environments may play an important role in healthcare and therapeutic applications.

According to Fortune Business Insights, the global autism spectrum disorder treatment market is projected to expand from approximately $9.2 billion in 2026 to more than $18 billion by 2034, growing at a compound annual growth rate of 9%.